CL vs JBS
Colgate-Palmolive vs Jbs N.V. — AI-powered side-by-side comparison
CL
Colgate-Palmolive
69
Insufficient Data
VS
| Metric | CL | JBS |
|---|
| AI Score |
69
|
61
|
| Price |
$92.32
|
$13.03
|
| P/E Ratio |
36.29×
|
17.96×
|
| ROE |
3948.1%
|
23.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
60.4%
|
11.9%
|
| Debt / Equity |
33.29×
|
0.00×
|
| Dividend Yield |
2.3%
|
7.7%
|
| RSI (14) |
56.5
|
41.6
|
| Beta |
0.322
|
0.1605
|
| Expected Upside |
+1.1%
|
—
|
AI Committee View
Current Innellis committee reasoning for CL versus JBS.
CL leads by 8 points.
CL scores 69/100 (Insufficient Data) versus JBS at 61/100 (Buy).
CL Committee View
100% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- Risk/reward is unfavorable: 2.5% downside vs 1.1% upside.
JBS Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 48.5% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 2.65) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- P/E of 8.2 is inexpensive for the broad market — Value
- ROE of 20.5% shows genuine earnings power backing the valuation — Value
- Dividend yield of 14.9% pays you to wait — Value
Bear Case
- Debt-to-equity of 2.65 adds balance-sheet risk to the value case — Value
- MACD histogram negative -- bearish momentum — Technical
- High leverage (debt-to-equity 2.65) amplifies downside in a stress scenario — Risk